Viewing Study NCT06201234


Ignite Creation Date: 2025-12-25 @ 2:34 AM
Ignite Modification Date: 2025-12-26 @ 1:10 AM
Study NCT ID: NCT06201234
Status: RECRUITING
Last Update Posted: 2025-12-01
First Post: 2023-12-07
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer
Sponsor: GBG Forschungs GmbH
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module